Abstract:The height-for-age and the BMI-for-age, as evaluated by z-scores, of children with ulcerative colitis (UC) did not differ from those of normal Danish children, but Crohn's disease (CD) children had significantly lower height and BMI values, both when compared to normal children and children with UC. In contrast to UC, CD is frequently complicated by malnutrition and growth retardation at the time of diagnosis.
“…Particularly significant growth retardation is observed when the disease is localized mainly in the small intestine, since up to 19% of these children reach the final height eight centimeters smaller than expected [4]. In the group of children with ulcerative colitis only 3-10% demonstrate a decreased growth rate at diagnosis [4,9]. Sometimes at the time of diagnosis not only growth retardation and sexual maturation retardation are observed, but also chronic, serious disturbances of bone mineralization in the form of severe osteoporosis, which are the first symptoms of IBD, are present as well [10].…”
Section: Etiology and Frequency Of Growth Disturbances In Children Wimentioning
confidence: 97%
“…Borrelli et al also demonstrated that the effect of that treatment was significantly better if the treatment was prolonged than if it was limited to induction with three doses of the drug [21]. Biologics directly affect bone metabolism and the reabsorption process in a mechanism independent of anti-inflammatory action [9]. In the studies of Malaise et al it was demonstrated that already after eight weeks of biologic treatment biochemical markers of bone formation (type-1 collagen C-te lopeptide, type-1 procollagen, osteocalcin, specific alka line phosphatase) were normalized in 14-51% of patients [22].…”
Section: Treatment Of Growth Disturbances In Children With Inflammatomentioning
“…Particularly significant growth retardation is observed when the disease is localized mainly in the small intestine, since up to 19% of these children reach the final height eight centimeters smaller than expected [4]. In the group of children with ulcerative colitis only 3-10% demonstrate a decreased growth rate at diagnosis [4,9]. Sometimes at the time of diagnosis not only growth retardation and sexual maturation retardation are observed, but also chronic, serious disturbances of bone mineralization in the form of severe osteoporosis, which are the first symptoms of IBD, are present as well [10].…”
Section: Etiology and Frequency Of Growth Disturbances In Children Wimentioning
confidence: 97%
“…Borrelli et al also demonstrated that the effect of that treatment was significantly better if the treatment was prolonged than if it was limited to induction with three doses of the drug [21]. Biologics directly affect bone metabolism and the reabsorption process in a mechanism independent of anti-inflammatory action [9]. In the studies of Malaise et al it was demonstrated that already after eight weeks of biologic treatment biochemical markers of bone formation (type-1 collagen C-te lopeptide, type-1 procollagen, osteocalcin, specific alka line phosphatase) were normalized in 14-51% of patients [22].…”
Section: Treatment Of Growth Disturbances In Children With Inflammatomentioning
“…At presentation, children with IBD and particularly CD are more likely to be short or growing slowly [1, 2]. The height of these children may be inversely related to the duration of symptoms and poor growth may be the sole presenting feature in some children [3].…”
Section: Evidence For Growth Retardation In Ibdmentioning
Background: Growth in children with inflammatory bowel disease (IBD) is affected through a number of mechanisms; controlling disease activity and supporting poor nutritional status are paramount in these patients. Further understanding of the basic mechanisms by which cytokines influence growth will facilitate the development of therapeutic modalities to improve growth. Conclusions: Clinical management that addresses growth and puberty in children with IBD should be a partnership between paediatric gastroenterologists and endocrinologists. Well-designed studies of growth-promoting hormonal treatment may answer questions regarding the efficacy and safety of treating growth retardation in the subgroup of patients who continue to fail to grow despite optimal management of their IBD.
“…Multiple studies have confirmed that mean height z-scores were significantly lower in children with CD, although the mean height z-scores of children with UC were not significantly lower [6,7]. Paerregaard et al [8] discovered that height and BMI z-scores of CD patients at diagnosis were significantly lower than those of UC patients, which did not differ from those of healthy children. In patients with Crohn's disease, Sawczekno et al [6] discovered that the presence of jejunal disease was associated with reduced weight and height, and that ileal disease was associated with reduced weight.…”
Pediatric patients with newly diagnosed Crohn's disease and the presence of ASCA antibodies have lower mean height and weight z-scores. This study provides evidence that specific subsets of children with Crohn's disease may be at greater risk of growth impairment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.